Bionomics Limited/fi Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Coastlands Capital LP and affiliated entities have filed an exit statement for their beneficial ownership of Neuphoria Therapeutics Inc. common stock, no longer holding over 5% of the class.
Baslake Partners, LP, along with its investment manager Baselake Management, LLC and managing member David Paolella, has disclosed a 4.1% beneficial ownership stake in Neuphoria Therapeutics Inc.
Coastlands Capital LP and related entities have reported a 5.1% beneficial ownership stake in Neuphoria Therapeutics Inc., holding 120,000 shares.
Baslake Partners, along with its management entity and managing member, has disclosed a 9.4% beneficial ownership stake in Neuphoria Therapeutics Inc.
Shay Capital LLC and Shay Capital Holdings LLC have reported a 7.3% beneficial ownership stake in Neuphoria Therapeutics Inc.
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Neuphoria Therapeutics Inc.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% of Neuphoria Therapeutics Inc.'s common stock as of December 31, 2024.